Trial Profile
A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects With Advanced Refractory Cancers
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Cisplatin/vinblastine (Primary) ; Ipilimumab (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer; Carcinoma; Cholangiocarcinoma; Chondrosarcoma; Chordoma; Colon cancer; Colorectal cancer; Head and neck cancer; Leiomyosarcoma; Liposarcoma; Liver cancer; Lung cancer; Lymphoma; Malignant melanoma; Pancreatic cancer; Sarcoma; Skin cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer
- Focus Adverse reactions
- Acronyms INTENSITY-IT-01; KEYNOTE A10
- Sponsors Intensity Therapeutics
- 02 Nov 2023 Results published in an Intensity Therapeutics Media Release.
- 02 Nov 2023 According to an Intensity Therapeutics media release, Dr. Christian Frederick Meyer, M.D., Ph.D., M.S is an investigator of this trial.
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.